| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Wolfram syndrome (WFS) is a very rare disease characterized by juvenile-onset insulin-dependent diabetes mellitus and optic atrophy, and there is still no established treatment. Our group was first to identify the causative gene (WFS1). Since then, research on WFS has been conducted both in Japan and overseas, but the fundamental mechanism leading to a cure has yet to be elucidated. In this study, we focused on ATP2A2 as the mechanism by which WFS causes decreased insulin secretion, and found that ATPA2a2 activators had an insulin-promoting effect in mice with decreased insulin secretion.
|
